Inhibition of MCF-7 breast cancer cell proliferation by 5α-dihydrotestosterone; a role for p21Cip1/Waf1

Journal of Molecular Endocrinology

Volumn 32, Issue 3, 2004, Pages 793-810

  Greeve, M A ^a,b   Allan, R K ^a,c   Harvey, J M ^b   Bentel, Jacky M ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c MURDOCH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

5ALPHA PREGNANE 3,20 DIONE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; PROTEIN P21; PROTEIN P27;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; PHASE TRANSITION; PRIORITY JOURNAL; PROTEIN BINDING;

BREAST NEOPLASMS; CDC2-CDC28 KINASES; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SHAPE; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; DIHYDROTESTOSTERONE; FEMALE; HUMANS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; RECEPTORS, ANDROGEN; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEINS;

EID: 3042737052     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/jme.0.0320793     Document Type: Article

References (75)

1. Altucci L, Addeo R, Cicatiello L, Dauvois S, Parker MG, Truss M, Beato M, Sica V, Bresciani F & Weisz A 1996 17 beta-oestradiol induces cyclin D1 gene transcription, p36D1-p34(cdk4) complex activation and p105Rb phosphorylation during mitogenic stimulation of G1-arrested human breast cancer. Oncogene 12 2315-2324.
2. Ando S, De Amicis F, Rago V, Carpino A, Maggiolini M, Panno M & Lanzino M 2002 Breast cancer: from oestrogen to androgen receptor. Molecular and Cellular Endocrinology 193 121-128.
3. Aprelikova O, Xiong Y & Liu ET 1995 Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. Journal of Biological Chemistry 270 18195-18197.
4. Birrell SN, Bentel JM, Hickey TE, Ricciardelli C, Weger MA, Horsfall DJ & Tilley WD 1995 Androgens induce divergent proliferative responses in human breast cancer cell lines. Journal of Steroid Biochemistry and Molecular Biology 52 459-467.
5. Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4. Journal of Biological Chemistry 272 23863-25872.
6. Kip1 abrogates antioestrogen-mediated cell cycle arrest in human breast cancer cells. PNAS 97 9042-9046.
7. Carroll JS, Prall OW, Musgrove EA & Sutherland RL 2000 A pure oestrogen antagonist inhibits cyclin E-Cdk2 activity in MCF-7 breast cancer cells and induces accumulation of p130-E2F4 complexes characteristic of quiescence. Journal of Biological Chemistry 275 38221-38229.
8. Kip1 protein: prognostic implications in primary breast cancer. Nature Medicine 3 227-230.
9. Cheng M, Olivier P, Dichl JA, Fero M, Roussel MF, Roberts JM & Sherr CJ 1999 The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO Journal 18 1571-1583.
10. Chu JS, Huang CS & Chang KJ 1999 p27 expression as a prognostic factor of breast cancer in Taiwan. Cancer Letters 141 123-130.
11. Connell-Crowley L, Harper JW & Goodrich DW 1997 Cyclin D1/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Molecular Biology of the Cell 8 287-301.
12. Cooperative Breast Cancer Group CBC 1964 Testosterone propionate therapy in breast cancer. Journal of the American Medical Association 188 1069-1072.
13. Dauvois S, Geng CS, Levesque C, Merand Y & Labrie F 1991 Additive inhibitory effects of an androgen and the antioestrogen EM-170 on oestradiol-stimulated growth of human ZR-75-71 breast tumours in athymic mice. Cancer Research 51 3131-3135.
14. Fernandez PL, Arce Y, Farre X, Martinez A, Nadal A, Rey MJ, Peiro N, Campo E & Cardesa A 1999 Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression. Journal of Pathology 187 563-566.
15. Gooch JL, Herrera RE & Yee D 2000 The role of p21 in interferon gamma-mediated growth inhibition of human breast cancer cells. Cell Growth and Diffirentiation 11 335-342.
16. Guo Y, Sklar GN, Borkowski A & Kyprianou N 1997 Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumour grade. Clinical Cancer Research 3 2269-2274.
17. Hackenberg R, Luttchens S, Hofmann J, Kunzmann R, Holzel F & Schulz KD 1991 Androgen sensitivity of the new human breast cancer cell line MFM-223. Cancer Research 51 5722-5727.
18. Harbour JW, Luo RX, Dei Santi A, Postigo AA & Dean DC 1999 Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98 859-869.
19. Hengst L, Gopfert U, Lashuel HA & Reed SI 1998 Complete inhibition of Cdk/cyclin by one molecule of p21 (Cip 1). Genes and Development 12 3882-3888.
20. Herzinger T & Reed SI 1998 Cyclin D3 is rate-limiting for the G1/S phase transition in fibroblasts. Journal of Biological Chemistry 273 14958-14961.
21. Hofman K, Swinnen JV, Verhoeven G & Heyns W 2001 E2F activity is biophysically regulated by androgens in LNCaP cells. Biochemical and Biophysical Research Commununications 283 97-101.
22. Ingle JN, Twito DI, Schaid DJ, Cullinan SA, Krook JE, Mailliard JA, Tschetter LK, Long HJ, Gerstner JG, Windschitl HE et al. 1991 Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer 67 886-891.
23. Jeffrey PD, Tong L & Pavletich NP 2000 Structural basis of inhibition of CDK cyclin complexes by INK4 inhibitors. Genes and Development 14 3115-3125.
24. Kemppainen JA, Lane MV, Sar M & Wilson EM 1992 Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. Journal of Biological Chemistry 267 968-974.
25. Kimura N, Mizokami A, Oonuma T, Sasano H & Nagura H 1993 Immunocytochemical localisation of androgen receptor with polyclonal antibody in paraffin-embedded human tissues. Journal of Histochemistry and Cytochemistry 41 671-678.
26. Krongrad A, Wilson CM, Wilson JD, Allman DR & McPhaul, MJ 1991 Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells. Molecular and Cellular Endocrinology 76 79-88.
27. LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A & Harlow E 1997 New functional activities for the p21 family of CDK inhibitors. Genes and Development 11 847-862.
28. WAF1/Cip1. Journal of Biological Chemistry 276 25823-25833.
29. Lapointe J & Labric C 2001 Role of the cyclin-dependent kinase inhibitor p27(Kip1) in androgen-induced inhibition of CAMA-1 breast cancer cell proliferation. Endocrinology 142 4331-4338.
30. de Launoit Y, Dauvois S, Dufour M, Simard J & Labrie F 1991 Inhibition of cell cycle kinetics and proliferation by the androgen 5 alpha-dihydrotestosterone and antioestrogen N,n-butyl-N-methyl-11-[16′ alpha-chloro-3′, 17 beta-dihydroxy-oestra-1′,3′,5′-(10′ triene-7′ alpha-yl] undecanamide in human breast cancer ZR-75 71 cells. Cancer Research 51 2797-2802.
31. Lea OA, Kvinnsland S & Thorsen T 1989 Improved measurement of androgen receptors in human breast cancer. Cancer Research 49 7162-7167.
32. Loden M, Nielsen NH, Roos G, Emdin SO & Landberg G 1999 Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation. Oncogene 18 2557-2566.
33. Lu S, Liu M, Epner DE, Tsai SY & Tsai MJ 1999 Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Molecular Endocrinology 13 376-384.
34. Lu S, Jenster G, & Epner DE 2000 Androgen induction of cyclin-dependent kinase inhibitor p21 gene: role of androgen receptor and transcription factor Sp1 complex. Molecular Endocrinology 14 753-760.
35. Lundberg AS & Weinberg RA 1998 Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin cdk complexes. Molecular and Cellular Biology 18 753-761.
36. McConnell BB, Gregory FJ, Stott FJ, Hara E & Peters G 1999 Induced expression of p16(INK4a) inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK inhibitor complexes. Molecular and Cellular Biology 19 1981-1989.
37. Marugo M, Bernasconi D, Miglietta L, Fazzuoli L, Ravera F, Cassulo S & Giordano G 1992 Effects of dihydrotestosterone and hydroxyflutamide on androgen receptors in cultured human breast cancer cells (EVSA-T). Journal of Steroid Biochemistry and Molecular Biology 42 547-554.
38. Kip1 in cell cycle arrest after androgen depletion in mouse mammary carcinoma cells (SC-3). Oncogene 17 2619-2627.
39. Mitra J, Dai CY, Somasundaram K, El-Deiry WS, Satyamoorthy K, Herlyn M & Enders GH 1999 Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumour suppressor p16(INK4a). Molecular and Cellular Biology 19 3916-3928.
40. Morgan DO 1996 The dynamics of cyclin dependent kinase structure. Current Opinions in Cell Biology 8 767-772.
41. Muraoka RS, Lenferink AE, Simpson J, Brantley DM, Roebuck LR, Yakes FM & Arteaga CL 2001 Cyclin-dependent kinase inhibitor p27(Kip1) is required for mouse mammary gland morphogenesis and function. Journal of Cell Biology 153 917-932.
42. Nemoto T, Ohara-Nemoto Y, Sato M & Ota M 1986 Stabilisation of androgen receptor by nonandrogenic steroids. Biochemistry International 12 701-705.
43. Ortmann J, Prifti S, Bohlmann MK, Rehberger-Schneider S, Strowitzki T & Rabe T 2002 Testosterone and 5 alpha-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecological Endocrinology 16 113-120.
44. INK4/MTS1 tumour suppressor gene product. EMBO Journal 14 503-511.
45. Parry D, Mahony D, Wills K & Lees E 1999 Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors. Molecular and Cellular Biology 19 1775-1783.
46. Perez-Roger I, Kim SH, Griffiths B, Sewing A & Land H 1999 Cyclins D1 and D2 mediate myc-incluced proliferation via sequestration of p27(Kip1) and p21(Cip1). EMBO Journal 18 5310-5320.
47. Planas-Silva MD & Weinberg RA 1997 Oestrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Molecular and Cellular Biology 17 4059-4069.
48. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78 59-66.
49. Poon RY & Hunter T 1995 Dephosphorylation of Cdk2 Thr160 by the cyclin-dependent kinase-interacting phosphatase KAP in the absence of cyclin. Science 270 90-93.
50. Poon RY, Toyoshima H & Hunter T 1995 Redistribution of the CDK inhibitor p27 between different cyclin CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation., Molecular Biology of the Cell 6 1197-1213.
51. Poulin R, Baker D & Labrie F 1988 Androgens inhibit basal and oestrogen-induced cell proliferation in the ZR-75-71 human breast cancer cell line. Breast Cancer Research and Treatment 12 213-225.
52. Poulin R, Simard J, Labrie C, Petitclerc L, Dumont M, Lagace L & Labrie F 1989 Down-regulation of estrogen receptors by androgens in the ZR-75-71 human breast cancer cell line. Endocrinology 125 392-399.
53. Prall OWJ, Sarcevic B, Musgrove EA, Watts CKW & Sutherland RL 1997 Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. Journal of Biological Chemistry 272 10882-10894.
54. Resnitzky D & Reed SI 1995 Different roles for cyclins D1 and E in regulation of the G1-to-S transition. Molecular and Cellular Biology 15 3463-3469.
55. Resnitzky D, Gossen M, Bujard H & Reed SI 1994 Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Molecular and Cellular Biology 14 1669-1679.
56. Reynisdottir I & Massague J 1997 The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 arid cdk2. Genes and Development 11 492-503.
57. Reynisdottir I, Polyak K, Iavarone A & Massague J 1995 Kip/Cip arid Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes and Development 9 1831-1845.
58. Russell A, Hendley J & Germain D 1999 Inhibitory effect of p21 in MCF-7 cells is overcome by its coordinated stabilisation with D-type cyclins. Oncogene 18 6454-6459.
59. CIP1 and Cdc25A: competition between an inhibitor and an activator of cyclin-dependent kinases. Molecular and Cellular Biology 17 4338-4345.
60. INK4B-complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells. Molecular and Cellular Biology 17 2458-2467.
61. Sangfelt O, Erickson S, Castro J, Heiden T, Gustafsson A, Einhorn S & Grander D 1999 Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene 18 2798-2810.
62. Kip1. Genes and Development 11 1464-1478.
63. Sherr CJ 1994 G1 phase progression: cycling on cue. Cell 79 551-555.
64. Sherr CJ & Roberts JM 1999 CDK inhibitors: positive and negative regulators of G1-phase progression. Genes and Development 13 1501-1512.
65. Cip1 is an antiestrogen regulated inhibitor of Cdk4 in human breast cancer cells. Journal of Biological Chemistry 7 5145-5152.
66. Soreide JA, Lea OA, Varhaug JE, Skarstein A & Kvinnsland S 1992 Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. European Journal of Surgical Oncology 18 112-118.
67. Swarbrick A, Lee CS, Sutherland RL & Musgrove EA 2000 Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells. Molecular and Cellular Biology 20 2581-2591.
68. Szelei J, Jimenez J, Soto AM, Luizzi MF & Sonnenschein C 1997 Androgen-induced inhibition of proliferation in human breast cancer MCF-7 cells transfected with androgen receptor. Endocrinology, 138 1406-1412.
69. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, Lavin P, Draetta G, Pagano M & Loda M 1997 The cell cycle inhibitor p27 is all independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Research 57 1259-1263.
70. Tormey DC, Lippman ME, Edwards BK & Cassidy JG 1983 Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Annals of Internal Medicine 98 139-144.
71. Kip1 in G1 arrest by high dose 5 alpha-dihydrotestosterone in LNCaP human prostate cancer cells. Oncogene 19 670-679.
72. Yang RM, Naitoh J, Murphy M, Wang HJ, Phillipson J, deKernion JB, Loda M & Reiter RE 1998 Low p27 expression predicts poor disease-free survival in patients with prostate cancer. Journal of Urology 159 941-945.
73. Yeap BB, Krueger RG & Leedman PJ 1999 Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells. Endocrinology 140 3282-3291.
74. Zhou J, Ng S, Adesanya-Famuiya O, Anderson K & Bondy CA 2000 Testosterone inhibits oestrogen-induced mammary epithelial proliferation and suppresses oestrogen receptor expression. FASEB Journal 14 1725-1730.
75. Zhou ZX, Lane MV, Kemppainen JA, French FS & Wilson EM 1995 Specificity of ligand-dependent androgen receptor stabilisation: receptor domain interactions influence ligand dissociation and receptor stability. Molecular Endocrinology 9 208-218.